Literature DB >> 25979655

Factor H-related proteins determine complement-activating surfaces.

Mihály Józsi1, Agustin Tortajada2, Barbara Uzonyi3, Elena Goicoechea de Jorge4, Santiago Rodríguez de Córdoba5.   

Abstract

Complement factor H-related proteins (FHRs) are strongly associated with different diseases involving complement dysregulation, which suggests a major role for these proteins regulating complement activation. Because FHRs are evolutionarily and structurally related to complement inhibitor factor H (FH), the initial assumption was that the FHRs are also negative complement regulators. Whereas weak complement inhibiting activities were originally reported for these molecules, recent developments indicate that FHRs may enhance complement activation, with important implications for the role of these proteins in health and disease. We review these findings here, and propose that FHRs represent a complex set of surface recognition molecules that, by competing with FH, provide improved discrimination of self and non-self surfaces and play a central role in determining appropriate activation of the complement pathway.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CFHRs; complement; disease susceptibility; factor H; factor H-related proteins

Mesh:

Substances:

Year:  2015        PMID: 25979655     DOI: 10.1016/j.it.2015.04.008

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  62 in total

1.  Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.

Authors:  Richard B Pouw; Mieke C Brouwer; Marlon de Gast; Anna E van Beek; Lambertus P van den Heuvel; Christoph Q Schmidt; Arie van der Ende; Pilar Sánchez-Corral; Taco W Kuijpers; Diana Wouters
Journal:  Blood Adv       Date:  2019-02-26

2.  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Authors:  Carole Seguin-Devaux; Jean-Marc Plesseria; Charlène Verschueren; Cécile Masquelier; Gilles Iserentant; Marie Fullana; Mihály Józsi; Jacques H M Cohen; Xavier Dervillez
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

3.  Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA.

Authors:  Jesús García-Fernández; Susana Vilches-Arroyo; Leticia Olavarrieta; Julián Pérez-Pérez; Santiago Rodríguez de Córdoba
Journal:  Methods Mol Biol       Date:  2021

Review 4.  How novel structures inform understanding of complement function.

Authors:  Elena Goicoechea de Jorge; Hugo Yebenes; Marina Serna; Agustín Tortajada; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  Semin Immunopathol       Date:  2017-08-14       Impact factor: 9.623

Review 5.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 6.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

7.  Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

Authors:  Paraskevas Iatropoulos; Erica Daina; Manuela Curreri; Rossella Piras; Elisabetta Valoti; Caterina Mele; Elena Bresin; Sara Gamba; Marta Alberti; Matteo Breno; Annalisa Perna; Serena Bettoni; Ettore Sabadini; Luisa Murer; Marina Vivarelli; Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-10-13       Impact factor: 10.121

Review 8.  C3 glomerulopathy - understanding a rare complement-driven renal disease.

Authors:  Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

9.  Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Authors:  Laura M Rogers; Sarah L Mott; Brian J Smith; Brian K Link; Deniz Sahin; George J Weiner
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

Review 10.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.